Diffusion Pharmaceuticals Inc. (DFFN)
Chart Events
Performance Outlook
| Previous Close | 0.5107 |
| Open | 0.5105 |
| Bid | 0.5050 x 900 |
| Ask | 0.5161 x 1000 |
| Day's Range | 0.5020 - 0.5159 |
| 52 Week Range | 0.4600 - 1.8500 |
| Volume | 392,063 |
| Avg. Volume | 1,544,236 |
| Market Cap | 52.481M |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2760 |
| Earnings Date | Aug 09, 2021 - Aug 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.00 |
- Simply Wall St.
We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Diffusion Pharmaceuticals Issues Letter to Shareholders
Figure 1. Effects of TSC on transcutaneous oxygen pressure (tcpO2). The graph was created by subtracting the median placebo response from the dose and time matched median TSC response. CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert C
- GlobeNewswire
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
Conference to Take Place Virtually, September 13-15, 2021CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference taking
